Layoffs have hit biopharma hard over the last year and a half. In this episode Fierce's Max Bayer and Gabrielle Mason will discuss the recent trends. We'll also cover a gene therapy by Sarepta Therapeutics, Abbott's FDA approval, plus this week's headlines.
To learn more about the topics in this episode:
"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.
See omnystudio.com/listener for privacy information.
A cell therapy reckoning
Automation, decentralization and the future of CAR-Ts: Advancements in cell & gene therapy manufacturing (Part III)
[Sponsored] Opportunities & Challenges of Digital Pathology Adoption in CDx Development
[Sponsored] Unlocking health equity: The promise of digital health technologies
Advancements in cell & gene therapy manufacturing (Part II)
Fulfilling the promise of cell & gene therapies through manufacturing (Part I)
A closer look at 2023's top biopharma deals and what lies ahead
A look at pharma revenue rankings
Winning formulas for the best biotech and drug names
[Sponsored] What does the future of specialist distribution look like?
Deep dive: Biopharma layoffs in Q1
The unrecognized threat of PAD
The top money raisers in biotech
A closer look at European biotech investment in 2024
Inclusivity in psoriasis trials with Takeda
Fierce Medtech's Fierce 15
[Sponsored] A Person-Centered Approach to Achieving Long-Term Success
CAR-T boxed warnings: What comes next?
Breaking down Eli Lilly’s ESG formula
Gene editing's next act
Create your
podcast in
minutes
It is Free
Pharmacy Podcast Network
Børsen Morgenbriefing
Sarah Westall - Business Game Changers
Startitup podcasty
Wall Street Breakfast